Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.

@article{Generaux2011ImpactOS,
  title={Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins.},
  author={Grant T Generaux and Fiorenza M Bonomo and Marta Johnson and Kelly M. Mahar Doan},
  journal={Xenobiotica; the fate of foreign compounds in biological systems},
  year={2011},
  volume={41 8},
  pages={639-51}
}
Statins are the preferred class of drugs for treating patients with atherosclerosis and related coronary heart disease. Treatment with statins leads to significant low-density lipoprotein cholesterol (LDL-C) lowering, resulting in reductions in major coronary and vascular events. Statins are generally well tolerated and safe; however, their use is complicated by infrequent, but often serious, muscular adverse events. For many statins, both efficacy and risk of adverse muscle events can be… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 15 extracted citations

Toxicokinetics and toxicity of atorvastatin in dogs.

Toxicology and applied pharmacology • 2015
View 7 Excerpts
Highly Influenced

Resistance and intolerance to statins.

Nutrition, metabolism, and cardiovascular diseases : NMCD • 2014
View 1 Excerpt

Similar Papers

Loading similar papers…